BioSpace News Archive

Novel DNA Manufacturing Platform Pioneering a New Generation of Faster, More Affordable CAR T Therapeutics. Offering Available to CRO/CMO Customers.

On September 28, 2018, the President signed the Department of Defense and Labor (DOD), Health and Human Services, and Education (LHHS) Appropriations Act of 2019, an appropriations bill that provides FY2019 funding for several important federal agencies, including the National Institutes for Health (NIH), Health Resources and Services Administration (HRSA), and Centers for Disease Control and Prevention (CDC).

More than 1,000 infectious disease specialists attending IDWeek 2018 in San Francisco feel it is time for deeper research into the role infectious agents play in triggering and accelerating Alzheimer’s disease, said Leslie Norins, M.D., Ph.D., CEO of Alzheimer’s Germ Quest, Inc., upon his return from the conference.

New Centralized Service Speeds Shipments and Reduces Import/Export Risk

Long term care support services have outpaced the 2.1% U.S. inflation rate[1] from 2017-2018.

Safety Net Connect leadership invited to participate in Ideas Exchange Conference presented by Medical Home Network

United Therapeutics Corporation and MannKind Corporation today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.

The biopesticide company Certis USA was named Member of the Year by the Biological Products Industry Alliance (BPIA) today.

EPHS Holdings Inc., together with its joint venture partner, Merritt Valley Cannabis, announced it received approval for their pending commercial cultivation license, identified as a license for Access to Cannabis for Medical Purposes Regulation (“ACMPR”), from Health Canada.

Phase I trial of single agent CK0801 for patients with Guillain-Barré Syndrome who have relapsed after intravenous immunoglobulin (IVIG) and/or plasmapheresis (PE) therapy to commerce